Faropenem for the management of infectious diseases – A systematic review of in vitro susceptibility tests and clinical studies
Abstract
This comprehensive review aimed to understand the activity and resistance pattern of faropenem compared to other antimicrobial agents. A literature search was performed using the PubMed database to identify studies published in the English language. The inclusion criteria were clinical studies involving adults and/or children with respiratory or urinary tract infections that evaluated faropenem use and resistance patterns compared to other antibiotics, in inpatient, outpatient, and/or preclinical settings. In vitro studies reporting the activity of faropenem against clinical isolates of bacteria were included in the study. Of 327 identified articles, two clinical and 21 in vitro studies were considered eligible. The clinical studies, which included adult patients with acute bacterial sinusitis, showed improvement with faropenem compared to cefuroxime. The in vitro studies indicated the activity of faropenem against Gram-positive (e.g., Streptococcus, Staphylococcus, Clostridium, and Enterococcus) and Gram-negative bacteria (e.g., Hemophilus influenzae, Escherichia coli, and Proteus, Pseudomonas, Citrobacter, and Bacteroides species) compared to amoxicillin-clavulanic acid combination, cefpodoxime, levofloxacin, and azithromycin. Faropenem also showed activity against β-lactamase–producing and penicillin-, ampicillin-, and methicillin-resistant strains. Faropenem exhibited antimicrobial activity against a broad spectrum of bacterial pathogens, including resistant strains.…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.